The Breast Cancer Liquid Biopsy Market is projected to reach USD 12.45 billion by 2033, growing from USD 4.03 billion in 2023, with an impressive compound annual growth rate (CAGR) of 20.45% over the forecast period. This market focuses on developing and utilizing non-invasive diagnostic tests that detect and monitor breast cancer through blood samples. These liquid biopsies analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers to assess the presence and progression of the disease. Compared to traditional tissue biopsies, liquid biopsies offer benefits such as reduced risk, faster results, and the ability to monitor treatment response and detect early recurrence. The growth of this market is driven by advancements in genomic technologies, a rising prevalence of cancer, and increasing demand for personalized medicine.
The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.
Segments covered
By Circulating Biomarker (Circulating Tumor Cells, Cell-free DNA, Extracellular Vesicles, Others)
By End User (Reference Laboratories, Hospitals and Physician Laboratories)
Key players
Roche Diagnostics
QIAGEN N.V
Bio-Rad Laboratories
Myriad Genetics
Menarini Silicon Biosystems
Illumina
Cynvenio Biosystems, Inc
Genomic Health, Inc
Thermo Fisher Scientific Inc.
FLUXION BIOSCIENCES, INC
- Chapter 1. Executive Summary
- Chapter 2. Scope Of The Study
- 2.1. Market Definition
- 2.2. Scope Of The Study
- 2.2.1. Objectives of Report
- 2.2.2. Limitations
- 2.3. Market Structure
- Chapter 3. Evolve BI Methodology
- Chapter 4. Market Insights and Trends
- 4.1. Supply/ Value Chain Analysis
- 4.1.1. Raw End Users Providers
- 4.1.2. Manufacturing Process
- 4.1.3. Distributors/Retailers
- 4.1.4. End-Use Industry
- 4.2. Porter’s Five Forces Analysis
- 4.2.1. Threat Of New Entrants
- 4.2.2. Bargaining Power Of Buyers
- 4.2.3. Bargaining Power Of Suppliers
- 4.2.4. Threat Of Substitutes
- 4.2.5. Industry Rivalry
- 4.3. Impact Of COVID-19 on the Breast Cancer Liquid Biopsy Market
- 4.3.1. Impact on Market Size
- 4.3.2. End-Use Industry Trend, Preferences, and Budget Impact
- 4.3.3. Regulatory Framework/Government Policies
- 4.3.4. Key Players' Strategy to Tackle Negative Impact
- 4.3.5. Opportunity Window
- 4.4. Technology Overview
- 12.28. Macro factor
- 4.6. Micro Factor
- 4.7. Demand Supply Gap Analysis of the Breast Cancer Liquid Biopsy Market
- 4.8. Import Analysis of the Breast Cancer Liquid Biopsy Market
- 4.9. Export Analysis of the Breast Cancer Liquid Biopsy Market
- Chapter 5. Market Dynamics
- 5.1. Introduction
- 5.2. DROC Analysis
- 5.2.1. Drivers
- 5.2.2. Restraints
- 5.2.3. Opportunities
- 5.2.4. Challenges
- 5.3. Patent Analysis
- 5.4. Industry Roadmap
- 5.5. Parent/Peer Market Analysis
- Chapter 6. Global Breast Cancer Liquid Biopsy Market, By Circulating Biomarker
- 6.1. Introduction
- 6.2. Circulating Tumor Cells
- 6.3. Cell-free DNA
- 6.4. Extracellular Vesicles
- 6.5. Others
- Chapter 7. Global Breast Cancer Liquid Biopsy Market, By End User
- 7.1. Introduction
- 7.2. Reference Laboratories
- 7.3. Hospitals and Physician Laboratories
- Chapter 8. Global Breast Cancer Liquid Biopsy Market, By Region
- 8.1. Introduction
- 8.2. North America
- 8.2.1. Introduction
- 8.2.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.3. Market Size and Forecast, By Country, 2023-2033
- 8.2.4. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.2.5. Market Size and Forecast, By End User, 2023-2033
- 8.2.6. US
- 8.2.6.1. Introduction
- 8.2.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.6.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.2.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.2.7. Canada
- 8.2.7.1. Introduction
- 8.2.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.7.4. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.2.7.5. Market Size and Forecast, By End User, 2023-2033
- 8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.3. Market Size and Forecast, By Country, 2023-2033
- 8.3.4. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.3.5. Market Size and Forecast, By End User, 2023-2033
- 8.3.6. Germany
- 8.3.6.1. Introduction
- 8.3.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.6.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.3.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.7. France
- 8.3.7.1. Introduction
- 8.3.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.7.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.3.7.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.8. UK
- 8.3.8.1. Introduction
- 8.3.8.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.8.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.3.8.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.9. Italy
- 8.3.9.1. Introduction
- 8.3.9.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.9.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.3.9.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.11. Rest Of Europe
- 8.3.11.1. Introduction
- 8.3.11.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.11.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.3.11.4. Market Size and Forecast, By End User, 2023-2033
- 8.4. Asia-Pacific
- 8.4.1. Introduction
- 8.4.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.3. Market Size and Forecast, By Country, 2023-2033
- 8.4.4. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.12.28. Market Size and Forecast, By End User, 2023-2033
- 8.4.6. China
- 8.4.6.1. Introduction
- 8.4.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.6.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.4.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.7. India
- 8.4.7.1. Introduction
- 8.4.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.7.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.4.7.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.8. Japan
- 8.4.8.1. Introduction
- 8.4.8.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.8.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.4.8.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.9. South Korea
- 8.4.9.1. Introduction
- 8.4.9.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.9.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.4.9.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.10. Rest Of Asia-Pacific
- 8.4.10.1. Introduction
- 8.4.10.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.10.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.4.10.4. Market Size and Forecast, By End User, 2023-2033
- 8.5. Rest Of The World (RoW)
- 8.5.1. Introduction
- 8.5.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.5.3. Market Size and Forecast, By Circulating Biomarker, 2023-2033
- 8.5.4. Market Size and Forecast, By End User, 2023-2033
- Chapter 9. Company Landscape
- 9.1. Introduction
- 9.2. Vendor Share Analysis
- 9.3. Key Development Analysis
- 9.4. Competitor Dashboard
- Chapter 10. Company Profiles
- 10.1. Roche Diagnostics
- 10.1.1. Business Overview
- 10.1.2. Government & Defense Analysis
- 10.1.2.1. Government & Defense – Existing/Funding
- 10.1.3. Product Portfolio
- 10.1.4. Recent Development and Strategies Adopted
- 10.1.5. SWOT Analysis
- 10.2. QIAGEN N.V
- 10.2.1. Business Overview
- 10.2.2. Government & Defense Analysis
- 10.2.2.1. Government & Defense – Existing/Funding
- 10.2.3. Product Portfolio
- 10.2.4. Recent Development and Strategies Adopted
- 10.2.5. SWOT Analysis
- 10.3. Bio-Rad Laboratories
- 10.3.1. Business Overview
- 10.3.2. Government & Defense Analysis
- 10.3.2.1. Government & Defense – Existing/Funding
- 10.3.3. Product Portfolio
- 10.3.4. Recent Development and Strategies Adopted
- 10.3.5. SWOT Analysis
- 10.4. Myriad Genetics
- 10.4.1. Business Overview
- 10.4.2. Government & Defense Analysis
- 10.4.2.1. Government & Defense – Existing/Funding
- 10.4.3. Product Portfolio
- 10.4.4. Recent Development and Strategies Adopted
- 10.12.28. SWOT Analysis
- 10.5. Menarini Silicon Biosystems
- 10.5.1. Business Overview
- 10.5.2. Government & Defense Analysis
- 10.5.2.1. Government & Defense – Existing/Funding
- 10.5.3. Product Portfolio
- 10.5.4. Recent Development and Strategies Adopted
- 10.5.5. SWOT Analysis
- 10.6. Illumina
- 10.6.1. Business Overview
- 10.6.2. Government & Defense Analysis
- 10.6.2.1. Government & Defense – Existing/Funding
- 10.6.3. Product Portfolio
- 10.6.4. Recent Development and Strategies Adopted
- 10.6.5. SWOT Analysis
- 10.7. Cynvenio Biosystems, Inc
- 10.7.1. Business Overview
- 10.7.2. Government & Defense Analysis
- 10.7.2.1. Government & Defense – Existing/Funding
- 10.7.3. Product Portfolio
- 10.7.4. Recent Development and Strategies Adopted
- 10.7.5. SWOT Analysis
- 10.8 Genomic Health, Inc
- 10.8.1. Business Overview
- 10.8.2. Government & Defense Analysis
- 10.8.2.1. Government & Defense – Existing/Funding
- 10.8.3. Product Portfolio
- 10.8.4. Recent Development and Strategies Adopted
- 10.8.5. SWOT Analysis
- 10.9 Thermo Fisher Scientific Inc.
- 10.9.1. Business Overview
- 10.9.2. Government & Defense Analysis
- 10.9.2.1. Government & Defense – Existing/Funding
- 10.9.3. Product Portfolio
- 10.9.4. Recent Development and Strategies Adopted
- 10.9.5. SWOT Analysis
- 10.10. FLUXION BIOSCIENCES, INC
- 10.10.1. Business Overview
- 10.10.2. Government & Defense Analysis
- 10.10.2.1. Government & Defense – Existing/Funding
- 10.10.3. Product Portfolio
- 10.10.4. Recent Development and Strategies Adopted
- 10.10.5. SWOT Analysis
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook